Open Orphan (ORPH) ShareSoc presentation 11th May 2020

Open Orphan Executive Chairman Cathal Friel presents an update at the ShareSoc Growth Company webinar 11th May 2020

Introduction from Mike Dennis, ShareSoc – 00:23

Cathal Friel, Executive Chairman, Open Orphan.
Introduction – 00:55
About Open Orphan – 01:33
Management team – 08:39
Complementary Services Business – 10:26
World’s first Coronavirus challenge model – 11:28
About hVIVO – 14:19
Vaccine and Pharmaceutical product portfolio – 15:39
Genomic data capturing – 17:06
Contracts – 17:53
Open Orphan strategy – 18:07
hVIVO strategy – 18:17
Combined pipeline – 18:20
Revenue synergies – 19:42
Revenue growth and profitability – 21:30
Q&A – 23:25

Open Orphan PLC is a European-focussed, rare and orphan drug consulting services platform. The company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.Venn Life Sciences Holdings PLC is engaged into a Clinical Research Organisation (CRO) providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.